Indication
- Gentamicin is an aminoglycoside antibiotic with a broad spectrum of activity against some Gram-positive bacteria, many Gram-negative bacteria including Pseudomonas aeruginosa.
- Generally used as the first line aminoglycoside, except in cystic fibrosis.
- For obese patients (actual body weight >120% of the ideal body weight), use ideal body weight to calculate gentamicin doses. Extrapolate estimated IBW from the height centiles on the growth chart.
Exclusion
Age |
Dose |
Frequency |
Route |
Neonate up to 1 month of age |
Refer to neonatal gentamicin monograph |
Child: 1 month to 17 years
|
7mg/kg
(maximum of 400mg)
Round dose to the nearest 10mg
|
24 hourly |
IV infusion over 60 minutes further diluted in sodium chloride 0·9% or glucose 5% up to a maximum of 100mL
Suggested dilution volumes:
- 1 year and under in 10mL
- 2 to 5 years in 50mL
- 9 years and over in 100mL
- smaller volumes can be used if required
|
Therapeutic drug monitoring
- Sample trough blood level between 18 and 24 hours AFTER END of first infusion.
- Aim for trough <1mg/L.
- If levels satisfactory, repeat after 3 to 4 days, or sooner if clinically indicated eg change in renal function. See note below on duration of treatment.
- If levels unsatisfactory seek advice from the clinical pharmacist or microbiology on dose or interval adjustment and re-sample BEFORE the third dose.
Supply
- 20mg in 2mL or 80mg in 2mL vials/ampoules.
Preparation
- Give as an IV infusion over 60 minutes further diluted in sodium chloride 0·9% or glucose 5% up to a maximum of 100mL.
- Ensure adequate flushing if patient is also prescribed a penicillin or cephalosporin, due to incompatibilty.
Compatibilities / incompatibilities
Monitoring / side effects
Renal function
- Prescribers should assess prior to prescribing and monitor whilst on treatment, and check child is passing urine. See link to Think Kidneys guidance below.
- Nephrotoxicity may be compounded by other agents eg amphotericin, cephalosporins, ciclosporin, indometacin, tacrolimus, vancomycin.
Auditory and vestibular function
- Prescribers should monitor for signs of ototoxicity and refer to audiology if it develops, or if gentamicin is continued for more than 7 days.
- Signs of ototoxicity include new tinnitus, dizziness, poor balance, hearing loss or oscillating vision.
- Stop gentamicin if ototoxicity occurs, and refer to microbiology or an infection specialist for advice on future therapy.
- Ototoxicity may be compounded by, eg, furosemide, and vancomycin. Monitor renal function and fluid balance closely.
NOTES
- Review the need for continuing treatment beyond 72 hours with a consultant microbiologist.
Contraindications
- Contra-indicated in patients with Myasthenia Gravis.
- Hypersensitivity to gentamicin or other ingredients.
Interactions
- Enhances the effects of non-depolarising muscle relaxants eg atracurium.
Licensed status